SCHEMBL4892309

SCHEMBL4892309

CC(=O)Nc1nc(/C=C/c2ccc(CC(=O)O)s2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 2/20 0.48
MAPT P10636 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
ABL1 P00519 4/20 0.40
LMNA P02545 3/20 0.40
POLB P06746 1/20 0.40
TYR P14679 1/20 0.39
MAPK1 P28482 2/20 0.38
AOC3 Q16853 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892315 1.00 KDM4E (0.48) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL973476 0.82 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883395 0.82 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883400 0.82 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL973475 0.82 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883404 0.82 KDM4E (0.51) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883440 0.82 ALDH1A1 (0.40) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883468 0.82 ALDH1A1 (0.40) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883445 0.82 ALDH1A1 (0.40) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4891163 0.82 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity ASTELLAS PHARMA INC. (JP) 2008-01-17 US disclosed
EP-1791835-A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY Astellas Pharma Inc. (JP) 2007-06-06 EP disclosed
WO-2006028269-A2 THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY ASTELLAS PHARMA INC. (JP) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity VCAM1, VAPB, VAPA KDM4E 3463/4885HSD17B10 1895/4885MAPT 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.